Personalized dietary intervention based on the reduction of carbohydrates and sugar intake in genetically predisposed individuals with the PNPLA3 at-risk genotype may lead to more effective clinical outcomes for NAFLD patients. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.